[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639327":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":52,"collaborators":12,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":56,"sex":62,"minAge":63,"maxAge":12,"enrollmentInfo":64,"targetDuration":12,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":73,"overallStatus":77,"whyStopped":12,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Ottawa Heart Institute Research Corporation","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard of Care Therapy","NO_INTERVENTION","Participants randomized to standard of care will receive the standard treatment for this condition.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Personlized Therapy with CYP2C19 genotyping","EXPERIMENTAL","Participants randomized to this arm will completed a point of care genotyping test to determine the presence or absence of the CYP2C19 gene, and the anti-platelet therapy will be determined by if the gene is present or not.",[18],"Drug: Genotyping guided therapy for anti-platelet management",[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":12},"DRUG","Genotyping guided therapy for anti-platelet management","Participants that are carriers of the CYP2C19 gene will receive either Ticagrelor monotherapy, or dual therapy with Ticagrelor and Aspirin.\n\nParticipants that are not carriers of the CYP2C19 gene will receive either Plavix monotherapy or dual therapy with Plavix and Aspirin.",[14],[26],{"name":27,"affiliation":5,"role":28},"Derek So, MD","PRINCIPAL_INVESTIGATOR",[30],{"name":31,"role":32,"phone":33,"phoneExt":12,"email":34},"Poppy MacPhee, RN","CONTACT","613-696-7000","pmacphee@ottawaheart.ca",[36],{"facility":37,"status":12,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"University of Ottawa Heart Institute","Ottawa","Ontario","K1Y 4W7","Canada","CA",{"type":44,"coordinates":45},"Point",[46,47],-75.69812,45.41117,{"lat":47,"lon":46},[50,51],{"name":31,"role":32,"phone":33,"phoneExt":12,"email":34},{"name":27,"role":28,"phone":12,"phoneExt":12,"email":12},{"type":53,"investigatorFullName":12,"investigatorTitle":12,"investigatorAffiliation":12,"oldNameTitle":12,"oldOrganization":12},"SPONSOR","100639327","phase-4-investigating-a-personalized-approach-to-anti-platelet-therapy-100639327",false,"NCT07602257","Investigating a Personalized Approach to Anti-Platelet Therapy","Reassessment of Anti-Platelet Therapy Using an Individualized Strategy With Pharmacogenomics to Refine Anti-Platelet Drugs in Vulnerable Patients to Eliminate Thrombotic and Bleeding Complications - A Cluster Randomized Pilot Study","RAPID PREVENT","Inclusion Criteria:\n\n* Age \\>18 years old\n* Receiving PCI with stenting\n\nExclusion Criteria:\n\n* Inability to take ticagrelor\n* Inability to take clopidogrel\n* Not expected to survive \\>48hours\n* Not able to complete a buccal swab","ALL","18 Years",{"count":65,"type":66},1760,"ESTIMATED","INTERVENTIONAL",[69],"PHASE4","RAPID PREVENT aims to identify if a personalized (targeted) anti-platelet strategy will reduce bleeding events when compared to the current standard anti-platelet therapy.",[72],"High Risk Bleeding",[74,75,76],"Thrombosis","bleeding complications","Anti-platelet therapy","NOT_YET_RECRUITING","2026-05-15",{"date":80,"type":81},"2026-05-22","ACTUAL",{"date":83,"type":66},"2026-06-01",{"date":85,"type":66},"2029-12-28",{"name":5,"class":6},1]